The biopharmaceutical industry's COVID-19 lessons learned
This report identifies 10 insights the biopharmaceutical industry has gathered so far as the world moves into the third year of the COVID-19 pandemic. We present them as hard-learned lessons to date – and as urgent strategies to end this pandemic and better prepare for the next one.
Download the report
#VaccinesForLife
Together we can give vaccines the greatest chance to make an even greater impact on our health, our communities, and our world. Discover our new global digital campaign #VaccinesForLife and join us on #TeamVaccines
Learn More
COVID-19 SOLUTIONS
Find out how the biopharmaceutical industry is using the power of innovation and science to tackle COVID-19 from all angles.
#AlwaysInnovating
New publication on technology transfer
Our publication, Technology Transfer: A Collaborative Approach to Improve Global Health, summarizes the current landscape for technology transfers, the 10 factors that enable success, and how different stakeholders can work together to deliver on prerequisites.
Read More
COVID-19
IFPMA members commit to accelerate their effort to use their skills, technology and resources to bring safe, effective diagnostics, treatments and vaccines to patients around the world. Visit IFPMA COVID-19 Hub.
Read More
The African Medicines Agency
AMA has the unique opportunity to become one of the most efficient and modern regulatory systems in the world.
Read More
AMR Action Fund
More than 20 leading pharmaceutical companies launched a ground-breaking collective venture - the AMR Action Fund - to bridge the current gap in funding for the development of new antibiotics
Read More
IFPMA Code of Practice eLearning
Our Code of Practice has evolved over time and it promotes a culture grounded on values, principles and decisions based on good judgement. You can take our new eLearning here!
Start training hereIFPMA in Brief
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Tackling Global health challenges
The research-based biopharmaceutical industry is proud to be playing its part in the quest to find effective and sustainable solutions to today’s most pressing health concerns.
Read More
Boosting Innovation and Access
The research-based biopharmaceutical industry is thinking creatively about its innovation and business models to meet new challenges, and is working in collaboration with different players from the scientific community.
Read More
Strengthening Regulatory Systems
Patients everywhere should be treated with high quality medicines and vaccines. Science-based guidelines provide direction for the development, manufacture, and supply of medicines.
Read More
Ethics and Business Integrity
The healthcare community and the public must be confident that research-based biopharmaceutical industry and their employees, wherever they operate, communicate and act in an ethical and professional manner.
Read More
Inventing Medicines and Vaccines
Never have people lived longer and never have so many children been saved from dying in the first years of life. Medicines and vaccines extend and improve the quality of life for many people.
Read More
Our Resources
Influenza vaccination during the COVID-19 pandemic
Read More
Why is flu vaccination so important during the COVID-19 pandemic?
IFPMA_HPP_Why is flu vaccination so important during the COVID-19 pandemic_Infographic
Read More
Three priorities to urgently increase access to COVID-19 vaccines
Innovative biopharmaceutical companies are at the forefront of the global effort to develop and manufacture safe and effective COVID-19 vaccines and treatments. Today, over 12 billion doses of vaccines have been produced, and more than 60 percent of the world’s population have received at least one dose.[1] Getting as many...
Read More
Greg Perry - IFPMA Moderated Panels @Pre-ICDRA 2018
Read More
IFPMA EFPIA PhRMA BIO ABPI Statement - Global COVID-19 Summit: Ending the Pandemic and Building Back Better
Innovative biopharmaceutical companies are at the forefront of the response to the pandemic; not least by developing and manufacturing COVID-19 vaccines in record time. Our industry joins today’s global summit to demonstrate our commitment towards working with governments and global health partners to align on a common vision to expand...
Read MoreJoin IFPMA
Our membership has three levels tailored to meet specific needs. Full Members have to be R&D-based pharmaceutical companies or national associations whose membership includes innovative pharmaceutical companies; Associate Members of R&D-based pharmaceutical companies and national associations whose permanent staff numbers are less than five, and Affiliate Members that are organizations, associations, companies and institutions who are supportive of the R&D-based
LEARN MOREOur Blog
A collective approach can improve access to quality cancer care
This article was originally published by Re:solve Global Health on 14 July 2022. The task of taking quality care to those living with cancer grows more difficult with the exploding number of new cases. A new initiative pools together expertise to widen access to timely and effective treatment. The global cancer population is significant and expanding. From over 19 million a year in 2020, the...
Read More
Caring for chronic diseases in lower-resource settings
This blog was originally published on Business & Industry on 29 June 2022. In the wake of COVID-19, lower-resourced settings need sustainable healthcare more than ever to build back better. Promising solutions are at hand. Each year, 41 million people die from heart disease, cancer, diabetes and chronic respiratory diseases[1]. This group of chronic diseases, called non-communicable diseases (NCDs), burden health systems and put people...
Read More
Collaboration can help find a vaccine within first 100 days
This blog was originally published on Health Awareness on 21 June 2022. We must take pandemic preparedness farther, faster by ensuring a joint response to future outbreaks. Our efforts against COVID-19 have surfaced critical learnings, including the need to establish a global foundational capability, fit for purpose ahead of the next health emergency. Key learnings for a better vaccine ecosystem We have witnessed the importance...
Read MoreLatest Tweets
